Teva Pharmaceutical Industries (NYSE:TEVA) Given New $26.00 Price Target at UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price lifted by UBS Group from $23.00 to $26.00 in a research note published on Wednesday,Benzinga reports. UBS Group currently has a buy rating on the stock.

Several other research analysts have also weighed in on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, Truist Financial started coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a “buy” rating and a $25.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $25.14.

Teva Pharmaceutical Industries Stock Down 0.9%

TEVA opened at $19.28 on Wednesday. The business has a 50 day simple moving average of $17.69 and a 200-day simple moving average of $16.66. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market capitalization of $22.11 billion, a P/E ratio of -120.51, a P/E/G ratio of 1.13 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries’s quarterly revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. raised its holdings in Teva Pharmaceutical Industries by 3.9% in the 4th quarter. Ameriprise Financial Inc. now owns 147,649 shares of the company’s stock valued at $3,254,000 after acquiring an additional 5,494 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Teva Pharmaceutical Industries by 122.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,048 shares of the company’s stock valued at $221,000 after purchasing an additional 5,526 shares during the last quarter. Vise Technologies Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $293,000. Mackenzie Financial Corp boosted its stake in Teva Pharmaceutical Industries by 4.1% in the 4th quarter. Mackenzie Financial Corp now owns 29,889 shares of the company’s stock worth $659,000 after buying an additional 1,171 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $214,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.